Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:HALO
CUSIP40637H10
Phone858-794-8889
Debt
Debt-to-Equity Ratio0.31
Current Ratio3.49
Quick Ratio3.43
Price-To-Earnings
Trailing P/E Ratio38.16
Forward P/E Ratio-20.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$316.61 million
Price / Sales7.83
Cash Flow$0.4602 per share
Price / Cash37.31
Book Value$1.46 per share
Price / Book11.76
Profitability
EPS (Most Recent Fiscal Year)$0.45
Net Income$62.97 million
Net Margins23.88%
Return on Equity38.10%
Return on Assets16.52%
Miscellaneous
Employees255
Outstanding Shares144,300,000
Market Cap$2.45 billion
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.06. The biopharmaceutical company earned $35.20 million during the quarter, compared to analyst estimates of $31.49 million. Halozyme Therapeutics had a net margin of 23.88% and a return on equity of 38.10%. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What price target have analysts set for HALO?
7 brokerages have issued 12 month target prices for Halozyme Therapeutics' stock. Their predictions range from $19.00 to $29.00. On average, they expect Halozyme Therapeutics' share price to reach $21.8571 in the next year. This suggests a possible upside of 27.3% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.
What is the consensus analysts' recommendation for Halozyme Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Qiagen (QGEN), bluebird bio (BLUE), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), argenx (ARGX), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA) and Rubius Therapeutics (RUBY).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 55)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
- Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
- Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)
Has Halozyme Therapeutics been receiving favorable news coverage?
Press coverage about HALO stock has been trending positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a media and rumor sentiment score of 0.26 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.53 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Halozyme Therapeutics.
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Third Security LLC (12.01%), BlackRock Inc. (8.50%), Iridian Asset Management LLC CT (5.74%), BB Biotech AG (5.73%), Artisan Partners Limited Partnership (1.19%) and Bank of New York Mellon Corp (1.19%). View Institutional Ownership Trends for Halozyme Therapeutics.
Which institutional investors are selling Halozyme Therapeutics stock?
HALO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Third Security LLC, Acadian Asset Management LLC, Baker BROS. Advisors LP, BB Biotech AG, Alambic Investment Management L.P., Chicago Equity Partners LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Halozyme Therapeutics.
Which institutional investors are buying Halozyme Therapeutics stock?
HALO stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Light Asset Management LLC, Dimensional Fund Advisors LP, Wells Fargo & Company MN, First Quadrant L P CA, First Trust Advisors LP, Colony Group LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $17.17.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.45 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
